Survey of Japanese nephrologists' use of clinical practice guidelines for rapidly progressive glomerulonephritis
© 2023. The Author(s), under exclusive licence to Japanese Society of Nephrology..
BACKGROUND: The guidelines in Japan for the treatment of rapidly progressive glomerulonephritis (RPGN) have been revised; the latest update was released in 2020. We investigated the actual usage of the new guidelines in Japan.
METHODS: We distributed a survey electronically to board-certified nephrologists throughout Japan from December 15, 2021 to January 31, 2022. The survey focused on anti-neutrophil cytoplasmic antibody (ANCA)-associated RPGN and anti-glomerular basement membrane (GBM)-antibody RPGN, plus the treatment strategies and infection-prevention measures used.
RESULTS: The survey was completed by 155 certified nephrologists from medical facilities across Japan. Their responses regarding treatment procedures revealed that ANCA-associated RPGN was treated with immunosuppressants and/or biologics by 58.1% of the survey respondents, and with plasma exchange (PE) in combination with corticosteroids by 21.3%. Regarding anti-GBM-antibody RPGN, 78.1% of the respondents used corticosteroids in combination with PE (63.2%), cyclophosphamide (CY) (23.9%), or rituximab (RTX) (8.4%), suggesting a discrepancy between clinical practice and the actual use of the guidelines. Trimethoprim-sulfamethoxazole was prescribed as prophylaxis by 94.8% of the respondents, reflecting the widespread recognition of the need to prevent infectious disease in patients with RPGN.
CONCLUSIONS: The survey responses revealed how Japan's new RPGN guidelines are used in actual clinical practice. Our findings will contribute to the guidelines' dissemination and implementation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical and experimental nephrology - 28(2024), 4 vom: 02. Apr., Seite 316-324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Takahashi-Kobayashi, Mayumi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ANCA-associated RPGN |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10157-023-02441-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366422529 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366422529 | ||
| 003 | DE-627 | ||
| 005 | 20240403235149.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10157-023-02441-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1363.xml |
| 035 | |a (DE-627)NLM366422529 | ||
| 035 | |a (NLM)38151607 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Takahashi-Kobayashi, Mayumi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Survey of Japanese nephrologists' use of clinical practice guidelines for rapidly progressive glomerulonephritis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Japanese Society of Nephrology. | ||
| 520 | |a BACKGROUND: The guidelines in Japan for the treatment of rapidly progressive glomerulonephritis (RPGN) have been revised; the latest update was released in 2020. We investigated the actual usage of the new guidelines in Japan | ||
| 520 | |a METHODS: We distributed a survey electronically to board-certified nephrologists throughout Japan from December 15, 2021 to January 31, 2022. The survey focused on anti-neutrophil cytoplasmic antibody (ANCA)-associated RPGN and anti-glomerular basement membrane (GBM)-antibody RPGN, plus the treatment strategies and infection-prevention measures used | ||
| 520 | |a RESULTS: The survey was completed by 155 certified nephrologists from medical facilities across Japan. Their responses regarding treatment procedures revealed that ANCA-associated RPGN was treated with immunosuppressants and/or biologics by 58.1% of the survey respondents, and with plasma exchange (PE) in combination with corticosteroids by 21.3%. Regarding anti-GBM-antibody RPGN, 78.1% of the respondents used corticosteroids in combination with PE (63.2%), cyclophosphamide (CY) (23.9%), or rituximab (RTX) (8.4%), suggesting a discrepancy between clinical practice and the actual use of the guidelines. Trimethoprim-sulfamethoxazole was prescribed as prophylaxis by 94.8% of the respondents, reflecting the widespread recognition of the need to prevent infectious disease in patients with RPGN | ||
| 520 | |a CONCLUSIONS: The survey responses revealed how Japan's new RPGN guidelines are used in actual clinical practice. Our findings will contribute to the guidelines' dissemination and implementation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ANCA-associated RPGN | |
| 650 | 4 | |a Anti-GBM-antibody RPGN | |
| 650 | 4 | |a Clinical practice guideline | |
| 650 | 4 | |a RPGN | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 700 | 1 | |a Sada, Ken-Ei |e verfasserin |4 aut | |
| 700 | 1 | |a Kawashima, Soko |e verfasserin |4 aut | |
| 700 | 1 | |a Miyawaki, Yoshia |e verfasserin |4 aut | |
| 700 | 1 | |a Nakazawa, Daigo |e verfasserin |4 aut | |
| 700 | 1 | |a Furuichi, Kengo |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Hirokazu |e verfasserin |4 aut | |
| 700 | 1 | |a Narita, Ichiei |e verfasserin |4 aut | |
| 700 | 1 | |a Usui, Joichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental nephrology |d 1998 |g 28(2024), 4 vom: 02. Apr., Seite 316-324 |w (DE-627)NLM096492473 |x 1437-7799 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:4 |g day:02 |g month:04 |g pages:316-324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10157-023-02441-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 4 |b 02 |c 04 |h 316-324 | ||